KMT Hepatech Inc. - In-Depth Company Writeup
KMT Hepatech Inc. is a leading company in the Medical and Health (MedTech) sector, specializing in the provision of advanced in vivo and in vitro preclinical research tools and services for drug development. Headquartered in Edmonton, Alberta, Canada, the company operates as a key North American production and service facility within the larger PhoenixBio Group. The company was founded in 2001 as a spin-off from the University of Alberta, leveraging groundbreaking research in liver cell transplantation. Its core mission is to accelerate the drug discovery and development process by providing highly translational, human-relevant preclinical models.
Continue…Core Business and Technological Focus
KMT Hepatech???s primary function is to supply and provide contract research services utilizing its proprietary platform technology: the chimeric mouse model with a humanized liver. This technology addresses a critical challenge in drug development: the interspecies differences in drug metabolism, efficacy, and toxicity that often render traditional rodent models poor predictors of human response. By utilizing a mouse model with a significant portion of its liver tissue replaced with normal, functional human hepatocytes (up to 95% engraftment), the company offers a system that provides clinically relevant data.
The research services are critically important for the pharmaceutical and biotechnology industries. The company concentrates its expertise in the following areas:
- Infectious Disease Studies: The humanized liver mouse model has become the gold standard for efficacy testing of therapeutics targeting liver-tropic pathogens, particularly Hepatitis B (HBV) and Hepatitis C (HCV). The model also has expanding applications in the study of other pathogens, such as the liver stage of Malaria.
- Human-Type Drug Metabolism and Pharmacokinetics (DMPK): Due to the presence of functional human hepatocytes, the model is invaluable for accurately characterizing human-specific metabolic pathways of drug candidates, including metabolite identification and assessment of enzyme induction/inhibition, which is crucial for predicting a drug's fate in the human body.
- Early Assessment of Human Hepatotoxicity and Safety: The model is utilized for safety assessment and toxicity studies, allowing researchers to evaluate the potential for drug-induced liver injury (DILI) in a human-relevant context long before clinical trials.
Products and Services Offered
KMT Hepatech offers a combination of proprietary research products and comprehensive contract research services.
1. Products
2. Contract Research Services
KMT Hepatech provides fully customized and executed studies to meet client-specific research objectives. These services utilize the PXB-Mouse® platform and are supported by a team of highly skilled scientific staff.
- Infectious Disease Efficacy Testing: Comprehensive studies to evaluate the therapeutic effect of new drug candidates and vaccines against liver-stage infectious diseases like HBV, HCV, and Malaria.
- Human Metabolite Profiling: Detailed studies to characterize the human-specific metabolites of a test compound to accurately predict human drug response and avoid late-stage failures due to species-specific metabolic differences.
- Hepatotoxicity and Safety Evaluation: Preclinical studies to determine the maximum tolerated dose and assess the potential for liver toxicity (hepatotoxicity) in a human-like system.
- Custom Evaluation Strategies: Collaborative research programs where the company???s scientists work closely with the client???s team to design and execute a tailored evaluation strategy that meets their priorities, budget, and timeline, ensuring a high level of assurance prior to the launch of clinical trials.
